← Apeloa Pharmaceutical overview

Apeloa Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Apeloa Pharmaceutical Co Ltd (000739.CS)

Q3 2026
▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

  • New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.

    These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.

  • Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.

    These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.

  • Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.

    This is a new, significant negative financial result that directly impacts valuation and investor confidence.

  • CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.

    This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

August 2026
▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

  • New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.

    These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.

  • Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.

    These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.

  • Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.

    This is a new, significant negative financial result that directly impacts valuation and investor confidence.

  • CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.

    This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

Latest
▲3▼1

Apeloa Expands Global Drug Pipeline, but Interim Profit Falls

  • New drug approvals broaden global reach Apeloa won several regulatory approvals: a European CEP for gabapentin, Chinese certificates for levocarnitine oral solution and pentoxifylline tablets, a Chinese API approval for cefditoren pivoxil, and US FDA approval for brivaracetam tablets. These open new markets and enrich the product line, supporting future sales.

    These approvals are new, concrete positive developments that expand Apeloa's addressable markets and product portfolio.

  • Biotech joint venture and WuXi partnership Apeloa invested 3.46 million yuan in a biotech joint venture and its subsidiary signed a five-year strategic cooperation with WuXi Biologics and Duoning Biotech. This moves Apeloa into high-growth biopharma and strengthens its large-molecule pipeline and supply chain.

    These are new strategic moves that position Apeloa in higher-growth areas and could drive long-term growth.

  • Interim profit and cash flow decline Apeloa's 2026 interim net profit fell 7.22% year-on-year to 522 million yuan, revenue dropped 11.41%, and operating cash flow plunged 81.75%. This weak financial performance weighs on investor sentiment and the stock price.

    This is a new, significant negative financial result that directly impacts valuation and investor confidence.

  • CRO sector rally lifts Apeloa shares On August 7, the A-share CRO sector surged over 7%, with Apeloa hitting the daily limit up. Strong earnings and order recovery across the sector, including WuXi AppTec's raised guidance, boosted sentiment and drove Apeloa's stock higher.

    This new sector-wide rally directly caused a sharp one-day price jump in Apeloa, reflecting positive industry momentum.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.